- Key learnings from real-world data and retrospective studies from nine abstracts are presented at the 62nd ASH Annual Meeting & Exposition, taking place virtually this year
- Takeda continues to gather and apply real-world evidence in the treatment of hemophilia, von Willebrand disease (VWD) and sickle cell disease (SCD) and advance personalized treatment in its ongoing commitment to people living with bleeding disorders
CAMBRIDGE, Mass. & OSAKA, Japan-Thursday 10 December 2020 [ AETOS Wire ]
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition that underscore its commitment to advancing treatments for rare bleeding disorders. Takeda will also be presenting data from its broader oncology portfolio and pipeline at the conference. Read more here.
Read more »